This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Journey Medical (DERM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Journey Medical (DERM) delivered earnings and revenue surprises of 25% and 10.55%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of 100% and 2.63%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
The Joint Corp. (JYNT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
The Joint (JYNT) delivered earnings and revenue surprises of -50% and 2.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of 20% and 23.75%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Profound Medical (PROF): Can Its 8.3% Jump Turn into More Strength?
by Zacks Equity Research
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last?
by Zacks Equity Research
Journey Medical (DERM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Journey Medical (DERM) Surges 9.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Journey Medical (DERM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Journey Medical Corporation (DERM) Tops Q4 Earnings Estimates
by Zacks Equity Research
Journey Medical (DERM) delivered earnings and revenue surprises of 136.36% and 1.84%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical Corporation (DERM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Journey Medical (DERM) delivered earnings and revenue surprises of 29.41% and 1.87%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Journey Medical (DERM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Journey Medical (DERM) delivered earnings and revenue surprises of -13.33% and 7.57%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 4.62% and 233.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last?
by Zacks Equity Research
4D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Amylyx Pharmaceuticals (AMLX) delivered earnings and revenue surprises of -291.67% and 21.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -59.62% and 0.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA
by Zacks Equity Research
Journey Medical (DERM) stock rises as the FDA accepts its regulatory filing for review seeking approval for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults.
Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
When Journey Medical (DERM) reports fourth-quarter 2023 results, investors will likely focus on the top and bottom-line numbers.
Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B
by Zacks Equity Research
Novo Nordisk (NVO) will acquire Catalent's three manufacturing sites from Novo Holdings to expand its manufacturing capacity.
Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) reports better-than-expected fiscal third-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.
Novo Nordisk (NVO) Q4 Earnings Top, GLP-1 Drugs Boost Sales
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected fourth-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.
AstraZeneca's (AZN) sBLA for Enhertu Gets FDA's Priority Tag
by Zacks Equity Research
AstraZeneca's (AZN) sBLA for Enhertu to treat metastatic HER2-positive solid tumors gets priority review status by the FDA. A final decision is expected in second-quarter 2024.
Apellis (APLS) Down on Negative CHMP Opinion for Pegcetacoplan
by Zacks Equity Research
Apellis (APLS) stock falls on the CHMP's negative recommendation to the EMA regarding the approval of intravitreal pegcetacoplan in the EU for the treatment of geographic atrophy secondary to age-related macular degeneration.
Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion
by Zacks Equity Research
Heron (HRTX) rises 19% on label expansion of its postoperative pain management drug, Zynrelef, to include additional orthopedic and soft tissue procedures.
Here's What Could Help Journey Medical Corporation (DERM) Maintain Its Recent Price Strength
by Zacks Equity Research
Journey Medical Corporation (DERM) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.